The stock of Coherus Biosciences Inc (NASDAQ:CHRS) is a huge mover today! The stock decreased 4.97% or $1.33 during the last trading session, hitting $25.45. About 496,181 shares traded hands or 28.56% up from the average. Coherus Biosciences Inc (NASDAQ:CHRS) has risen 88.72% since February 29, 2016 and is uptrending. It has outperformed by 76.51% the S&P500.
The move comes after 9 months negative chart setup for the $1.12 billion company. It was reported on Oct, 4 by Barchart.com. We have $23.41 PT which if reached, will make NASDAQ:CHRS worth $89.60M less.
Analysts await Coherus Biosciences Inc (NASDAQ:CHRS) to report earnings on November, 14. They expect $-1.71 earnings per share, up 8.06% or $0.15 from last year’s $-1.86 per share. After $-1.72 actual earnings per share reported by Coherus Biosciences Inc for the previous quarter, Wall Street now forecasts -0.58% EPS growth.
Coherus Biosciences Inc (NASDAQ:CHRS) Ratings Coverage
Out of 5 analysts covering Coherus Biosciences (NASDAQ:CHRS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Coherus Biosciences has been the topic of 5 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The stock of Coherus Biosciences Inc (NASDAQ:CHRS) has “Buy” rating given on Wednesday, September 7 by Maxim Group. The firm earned “Hold” rating on Thursday, September 3 by Zacks. As per Wednesday, July 27, the company rating was initiated by Citigroup. The stock has “Outperform” rating given by Credit Suisse on Wednesday, January 20. On Monday, November 23 the stock rating was initiated by Barclays Capital with “Overweight”.
According to Zacks Investment Research, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.”
Insitutional Activity: The institutional sentiment increased to 3.32 in 2016 Q2. Its up 1.99, from 1.33 in 2016Q1. The ratio improved, as 10 funds sold all Coherus Biosciences Inc shares owned while 9 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 49.39 million shares or 180.37% more from 17.62 million shares in 2016Q1.
Moreover, Highland Capital Mgmt L P has 0.23% invested in Coherus Biosciences Inc (NASDAQ:CHRS) for 327,044 shares. Columbus Circle Invsts accumulated 373,249 shares or 0.06% of the stock. Cam Group Inc A S has 0.05% invested in the company for 151,000 shares. Royal Natl Bank Of Canada has invested 0% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Kohlberg Kravis Roberts And Limited Partnership has 0.54% invested in the company for 3.06 million shares. The New York-based Springbok Capital Limited Co has invested 0.01% in Coherus Biosciences Inc (NASDAQ:CHRS). The Vermont-based Birchview Cap Lp has invested 0.09% in Coherus Biosciences Inc (NASDAQ:CHRS). Legal & General Public Limited Co last reported 4,114 shares in the company. Manufacturers Life Insurance The has invested 0% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Geode Limited Liability Corporation last reported 0% of its portfolio in the stock. Jacobs Levy Equity Management accumulated 12,800 shares or 0% of the stock. State Street owns 458,878 shares or 0% of their US portfolio. Trexquant Inv Limited Partnership holds 20,039 shares or 0.04% of its portfolio. Schwab Charles Investment Mngmt owns 106,337 shares or 0% of their US portfolio. New York State Common Retirement Fund holds 0% or 30,200 shares in its portfolio.
More notable recent Coherus Biosciences Inc (NASDAQ:CHRS) news were published by: Globenewswire.com which released: “Coherus BioSciences Regains Development and Commercial Rights to CHS-0214 From …” on September 27, 2016, also Benzinga.com with their article: “Coherus Biosciences Could Be First-To-Market With A Neulasta Biosimilar” published on October 03, 2016, Fool.com published: “Why Coherus BioSciences Inc. Shares Burst Today” on April 01, 2015. More interesting news about Coherus Biosciences Inc (NASDAQ:CHRS) were released by: Globenewswire.com and their article: “Coherus BioSciences Announces New Employment Inducement Grants” published on September 16, 2016 as well as Fool.com‘s news article titled: “Coherus Biosciences and Baxalta Take Aim at Amgen and Pfizer” with publication date: January 12, 2016.
CHRS Company Profile
Coherus BioSciences, Inc., incorporated on September 29, 2010, is a late-stage clinical biologics platform company. The Firm is focused on the global biosimilar market. The Firm operates through developing and commercializing biosimilar products segment. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.